Dequet C R, Wallace D J
Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Curr Opin Investig Drugs. 2001 Aug;2(8):1045-53.
This review highlights the advances made in the use of biological and immunomodulatory agents in systemic lupus erythematosus. Although there have been disappointments (eg, anti-CD40 ligand, DNAse), it is clear that DHEA and mycophenolate mofetil will have a place in the management of the disease. In our opinion, leflunomide and LJP-394 are the most promising therapies currently, under study.
本综述重点介绍了生物制剂和免疫调节剂在系统性红斑狼疮治疗中的进展。尽管也有令人失望之处（如抗CD40配体、脱氧核糖核酸酶），但显然脱氢表雄酮和霉酚酸酯在该病的治疗中将占有一席之地。我们认为，来氟米特和LJP - 394是目前正在研究的最有前景的疗法。
